Mast Therapeutics
  • About Us
    • CEO Blog
    • Management
    • Board of Directors
    • Regulatory Advisory Board
  • Technology
    • Product Candidates
    • Publications
  • Patient Resources
    • Clinical Trials
    • Additional Resources
    • What is Sickle Cell Disease?
  • Investors
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Analyst Coverage
    • Investor FAQ
  • News
  • Media
  • Contact

Site Map

  • Welcome To Mast Therapeutics
  • About Us
    • Letter from the CEO
    • Management
    • Board of Directors
  • Technology
    • MST-188 (purified poloxamer 188)
    • Exelbineâ„¢, or ANX-530 (vinorelbine injectable emulsion)
    • ANX-514 (docetaxel for injectable emulsion)
  • Investors
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Analyst Coverage
    • Investor FAQ
  • Media Center
  • Patient Resources
    • Clinical Trials
    • Additional Resources
      • SCD Community Organizations (United States)
      • SCD Community Organizations (International)
      • Sickle Cell Disease in the News
      • SCD Links
  • Contact
  • Careers
  • Terms and Conditions of Use
    • Privacy Statement

 

News

Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more

Technology

Click here to learn more about our lead product candidate, MST-188, as well as our other technologies. read more

Clinical Trials

We have initiated a Phase 3 clinical study of MST-188 for the treatment of sickle cell disease. See our Clinical Trials page for more info. read more

Copyright © 2013 Mast Therapeutics, Inc.

  • About Mast Therapeutics
  • Site Map
  • Terms of Use & Privacy